文献速递肝病

瑞典普通人群中潜在未诊断的MASH负担沉重

High burden of potentially undiagnosed MASH in a general population in Sweden.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-10-27

基于瑞典斯德哥尔摩2010-2020年常规临床实验室数据,使用纤维化NASH指数(FNI)对162,456例患者进行风险分层,发现23%为高风险、39%为低风险。高风险FNI组发生主要不良肝脏结局(MALO)的风险显著高于低风险组(aHR=4.6),而确诊MASH患者发生MALO的风险更高(aHR=6.73),且近半数确诊时已有MALO。

要点

  • 普通人群中约23%存在FNI高风险,提示潜在未诊断的纤维化MASH负担大。
  • 高风险FNI组MALO发生率显著高于低风险组(aHR=4.6),需早期识别。
  • 确诊MASH时近半数已有MALO,强调早期诊断的必要性。

核心结论

  • 普通人群中存在大量潜在未诊断的at-risk MASH,且确诊MASH时近半数已发生MALO,需更早诊断。

研究设计与样本

  • 基于瑞典斯德哥尔摩2010-2020年常规临床实验室数据的回顾性队列研究,使用FNI进行风险分层,并与1998-2022年确诊MASH患者比较结局。

主要发现

  • FNI可评估162,456例患者,其中23%为高风险,39%为低风险。
  • 确诊MASH患者基线MALO患病率为45%,高风险FNI组为0.6%。
  • 高风险FNI组较确诊MASH组MALO发生率更低(aHR=6.73,95%CI=4.03-11.23)。
  • 高风险FNI组较低风险组MALO发生率更高(aHR=4.6,95%CI=3.9-5.4)。
  • 高风险FNI组较低风险组MACE发生率更高(aHR=1.8,95%CI=1.7-1.8),但与确诊MASH组无显著差异(aHR=0.6,95%CI=0.3-1.2)。

关键数值与推荐

  • 高风险FNI定义为FNI≥0.33且至少1个心脏代谢危险因素;低风险定义为FNI<0.1±心脏代谢危险因素。
  • 确诊MASH定义为瑞典专科医疗中记录的ICD-10代码K75.8。

临床怎么用

  • 在具有心脏代谢危险因素的普通人群中使用FNI识别高风险个体,以便早期干预和监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Few studies have explored the prevalence and outcomes of fibrotic metabolic dysfunction-associated steatohepatitis (MASH) in the general population. We aimed to characterize patients at risk of MASH using the validated Fibrotic NASH Index (FNI) and to compare the incidence of major adverse liver outcomes (MALO), major adverse cardiovascular events (MACE) and mortality between FNI risk groups and patients with established MASH. METHODS: Patients were classified as high risk (FNI≥0.33 and ≥ 1 cardiometabolic risk factor), or low-risk (FNI<0.1 +/- cardiometabolic risk factors) using laboratory data from routine clinical care in Stockholm, Sweden in 2010-2020. Patients with established MASH had a recorded ICD-10 code (K75.8) in Swedish specialist care (1998-2022). Data were analysed using Cox regression models and MALO, MACE and mortality were measured in number of events, cumulative incidence, and incidence rates. RESULTS: FNI was available in 162,456 patients, of which 23% were considered at high risk of MASH, and 39% considered low-risk. Among patients with established MASH (n=615), MALO's were more common than in high-risk FNI patients (45% vs 0.6%) at baseline. The rate of incident MALO was higher in diagnosed MASH patients vs the high-risk FNI group (adjusted HR [aHR]=6.73, 95%CI=4.03-11.23) and higher in high vs low-risk FNI group (aHR=4.6, 95%CI=3.9-5.4). The rate of MACE was also higher in high- vs low-risk (aHR=1.8, 95%CI=1.7-1.8) but not significantly different in high-risk vs diagnosed patients (aHR=0.6, 95%CI=0.3-1.2). CONCLUSION: There is a large burden of potentially undiagnosed at-risk MASH in patients from a general population with risk factors for MASH. Almost half of patients with established MASH already have MALO at baseline, reinforcing the need for earlier diagnosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Grip ET, Basuroy R, Johansen P, et al. High burden of potentially undiagnosed MASH in a general population in Sweden. Clin Gastroenterol Hepatol. 2026. PMID: 42946109. doi:10.1016/j.cgh.2026.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。